Dianthus Therapeutics Is Up 320% in a Year.
One Major Investor Just Reduced Its Stake but Still Seems Bullish Octagon Capital Advisors cut its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing
What happened According to a SEC filing dated May 15, 2026, Octagon Capital Advisors reduced its holding in Dianthus Therapeutics by 470,000 shares during the first quarter. The estimated value of the shares sold was $27.22 million, based on the average closing price for the quarter. The quarter-end value of the remaining stake rose by $63.77 million, a change reflecting both share sales and stock price appreciation.
What else to know – Octagon Capital Advisors’ post-sale stake in Dianthus Therapeutics represents 18.08% of its 13F assets under management – Top holdings after the filing: – NASDAQ: DNTH: $163.36 million (18.1% of AUM) – NASDAQ:COGT: $90.45 million (10.0% of AUM) – NASDAQ:ABVX: $75.38 million (8.3% of AUM) – NASDAQ:ALMS: $62.36 million (6.9% of AUM) – NASDAQ:DFTX: $46.12 million (5.1% of AUM) – – As of May 14, 2026, shares of Dianthus Therapeutics were priced at $85.34, up about 320% over the past year, compared to a 25% gain from the S&P 500. Company Overview Company Snapshot – Dianthus Therapeutics develops novel monoclonal antibody therapies targeting severe autoimmune and inflammatory diseases. – The firm operates a clinical-stage biotechnology business model focused on the research and development of proprietary biologic drug candidates. – It serves patients with severe autoimmune and inflammatory disorders. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company based in New York City, specializing in the development of monoclonal antibody therapies for severe immune-mediated diseases.